Hemolytic Disease of the Fetus and Newborn (HDFN): What Pediatric Providers Need to Know When Managing Hemolytic Disease in Newb

Hemolytic Disease of the Fetus and Newborn (HDFN): What Pediatric Providers Need to Know When Managing Hemolytic Disease in Newborns (HDN)

Hemolytic Disease of the Fetus and Newborn (HDFN): What Pediatric Providers Need to Know When Managing Hemolytic Disease in Newborns (HDN)
RestartResume

Hear highlights from an AAP satellite symposium, including insight based on a patient’s journey and tips for the multidisciplinary management of HDFN.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

  • Overview

    What are the essential steps in managing hemolytic disease of the fetus and newborn (HDFN)? How soon after “the cord has been cut” does newborn care transfer from the maternal-fetal medicine specialist and ob-gyn to the pediatric team? At a recent satellite symposium of the American Academy of Pediatrics, Dr. James Bussel, Dr. Kara Markham, and Bethany Weathersby presented the latest data regarding current and emerging practice patterns and highlighted the critical need for improved understanding and multidisciplinary collaboration in the area of HDFN. Tune in to hear Dr. Markham summarize how diagnosis, care, and treatment have evolved—plus insights on how these might change the way you practice.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kara B. Markham, MD
    Associate Professor of Clinical Obstetrics & Gynecology
    University of Cincinnati
    Cincinnati, OH

    Research: Janssen Pharmaceuticals
    Consulting Fees: Janssen Pharmaceuticals

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the pathophysiology underlying fetal/newborn alloimmune disorders, with a focus on HDN
    • Identify current diagnostic and treatment regimens for managing the physiologic consequences of HDF and HDN
    • Explain the role of the neonatal Fc receptor pathway as a therapeutic means to address HDFN
    • Explain the psychological and social impact of HDF/HDN on the patient and family
  • Target Audience

    This activity is designed to meet the educational needs of neonatologists, pediatricians, pediatric NPs, PAs, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until December 6, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free